Related Experiment Video

Updated: Jun 12, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes

Thanh M Nguyen1, Venkat S Renukuntla, Rubina A Heptulla

  • 1Department of Pediatrics-Endocrinology Section, Nemours Children's Clinic, Jacksonville, Florida, USA.

Diabetes Care
|May 28, 2010
PubMed

Insights

Mixing insulin detemir with insulin aspart showed equivalent blood glucose control compared to separate injections in children with type 1 diabetes. This offers a convenient option for pediatric diabetes management.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Mellitus Management
  • Pharmacology

Background:

  • Type 1 diabetes (T1D) requires careful blood glucose management in children.
  • Insulin therapy is a cornerstone of T1D treatment.
  • Convenience in insulin administration is crucial for adherence in pediatric patients.

Purpose of the Study:

  • To compare the efficacy of mixed insulin detemir and aspart versus separate injections in pediatric T1D patients.
  • To evaluate blood glucose control parameters between the two administration methods.

Main Methods:

  • A crossover study design involving 14 children with T1D.
  • Participants received both mixed and separate insulin injections over two 10-day periods.
  • Continuous glucose monitoring (CGM) was utilized for 72 hours during each study period.

Main Results:

  • No significant differences were observed in the 48-hour area under the glucose curve (AUC) between mixed and separate injections (P = 0.58).
  • M-values, indicating glucose stability, were also comparable (P = 0.98).
  • Mean amplitude of glucose excursion (MAGE) showed no significant difference (P = 0.42).

Conclusions:

  • Administering insulin detemir mixed with insulin aspart is therapeutically equivalent to separate injections for blood glucose control in children with T1D.
  • This finding supports the potential for simplified insulin regimens in pediatric diabetes care.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...